Introduction

Knee osteoarthritis is a widespread and progressive condition where the protective cartilage in the knee gradually breaks down. This leads to pain, stiffness and a loss of mobility, affecting millions and often impacting day-to-day life. While many turn to standard treatments such as physiotherapy, pain relief or surgery, there is growing interest in newer options – like Arthrosamid knee injections.

Arthrosamid injections can offer a fresh approach, but understanding both their benefits and safety considerations is essential. In this article, we look specifically at who should avoid Arthrosamid injections and why, so patients and healthcare professionals can make well-informed decisions.

Understanding Arthrosamid Knee Injections and Their Intended Use

Arthrosamid is a synthetic gel made from a compound called polyacrylamide, injected directly into the knee joint. The gel acts as a cushioning filler and lubricant, working to ease pain by supporting or protecting damaged cartilage. To put it simply, it helps smooth the joint’s movement.

It’s important to realise that Arthrosamid works differently to other common knee injections. For instance, corticosteroid injections reduce inflammation, while hyaluronic acid helps improve joint fluid quality. Arthrosamid, on the other hand, provides a physical cushion. Research explains that “Polyacrylamide (PAAG) hydrogel is a novel compound recently introduced in the UK under the name Arthrosamid for osteoarthritis treatment.”

This treatment tends to be recommended for those experiencing moderate knee osteoarthritis symptoms who haven’t found enough relief from usual treatments but aren’t yet ready for knee replacement surgery. Careful patient selection is crucial. Studies also reassure that “Injection of PAAG hydrogel… has been shown to be safe with no long-lasting adverse events reported,” emphasising the importance of appropriate candidate assessment.

Who Is Not Suitable? Contraindications and Red Flag Criteria

Arthrosamid injections are not suitable for everyone. Those with allergies to polyacrylamide or related substances must avoid it to prevent severe allergic reactions.

Active or recent infections in the knee or elsewhere also rule out this treatment, as injecting into infected tissue risks spreading the infection, potentially causing serious joint problems.

People with weakened immune systems – whether from medication like chemotherapy or health conditions such as HIV – face greater infection risks and slower healing, so Arthrosamid should be deferred until their condition improves.

Similarly, anyone currently immunosuppressed should avoid arthrosamid injections until their health stabilises. Patients with bleeding disorders or those on blood thinners also need careful evaluation due to heightened bleeding risk during injection.

These warnings highlight why a thorough medical history and examination must come before considering Arthrosamid, ensuring patients’ safety is never compromised.

Weighing the Risks: Recognising Red Flag Symptoms and Alternatives

Both patients and clinicians should be watchful for warning signs that indicate Arthrosamid injections shouldn’t proceed. Sudden swelling, redness, warmth or tenderness around the knee could mean infection or inflammation. Likewise, symptoms like fever or general unwellness require medical assessment first.

In comparison with other injection options, Arthrosamid carries some unique risks linked to its synthetic gel nature. While corticosteroids offer quick inflammation relief but may harm cartilage over time, hyaluronic acid is usually safe, with varying effectiveness.

Encouragingly, Arthrosamid has proven lasting effects: “Statistically significant data was identified at 52 weeks and 13 months, indicating the efficacy of PAAG hydrogel at one year post-injection.” Another study adds that “iPAAG offers comparable short-term efficacy and modest advantage at 6 months, although long-term superiority is more limited,” positioning Arthrosamid as one option in the broader treatment landscape.

Laboratory research also supports its safety: “At tested concentrations and timepoints, 2.5 iPAAG had no significant adverse effects on nerve cells or their networks.”

For those unsuitable for Arthrosamid, effective alternatives include corticosteroids, hyaluronic acid injections, physiotherapy, weight management and pain relief. Surgery remains a last resort when these treatments aren’t enough.

The Role of Expert Guidance and Professional Care

Because the decision to use Arthrosamid is complex, expert involvement is essential. Consulting an experienced orthopaedic or musculoskeletal (MSK) specialist ensures thorough assessment and careful treatment planning.

Professor Paul Lee, a respected cartilage specialist and Regional Surgical Ambassador with the Royal College of Surgeons of Edinburgh, exemplifies the expert care beneficial in such scenarios. His expertise highlights the importance of personalised, evidence-based treatment.

At MSK Doctors, patients receive professional, compassionate care in a safe environment that prioritises best practice and patient safety. Although no treatment can guarantee perfect results, expert-led care offers the best chance of a positive outcome.

Conclusion

Knowing who should avoid Arthrosamid knee injections is key to safe, effective management of osteoarthritis. Recognising contraindications such as allergies, infections, immune suppression and bleeding risks – and working closely with experienced healthcare professionals – protects patients from avoidable harm.

With proper assessment and guidance, treatments like Arthrosamid can be valuable tools, tailored to each individual’s needs. When selected and administered thoughtfully, these innovative options can help ease osteoarthritis symptoms and improve quality of life.

References

• Cole, A., Maulana, R., Whitehead, J., & Lee, P. (2022). A systematic review of the novel compound Arthrosamid polyacrylamide (PAAG) hydrogel for treatment of knee osteoarthritis. Medical Research Archives, 10(8). https://doi.org/10.18103/mra.v10i8.2950
• Aykaç, B., Dinç, M., Nar, Ö. O., Karasu, R., & Bayrak, H. Ç. (2025). Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. Medicine, 104(6). https://doi.org/10.1097/MD.0000000000044655
• Walmod, P. S., Kusk, P., Jøhnk, N., Ankorina-Stark, I., & Essex, A. (2025). An injectable 2.5% cross-linked polyacrylamide hydrogel (2.5 iPAAG) demonstrates no neurotoxicity in human induced pluripotent stem cells-derived iCell® GlutaNeurons. Frontiers in Toxicology. https://doi.org/10.3389/ftox.2025.1585430